CIK 0001785530
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Werewolf Therapeutics, Inc.
Sign in to watch- Ticker
- HOWL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 823523180
- Phone
- +1 617-952-0555
- Business address
- 303 WYMAN STREET, SUITE 300, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-14 | EVNIN LUKE Director | Sale 10b5-1 | −39,560 | $0.93 | $37K | 3,552,501 |
| 2025-11-13 | MPM BioVentures 2014, L.P. 10% owner | Sale 10b5-1 | −90,951 | $0.98 | $89K | 5,600,240 |
| 2025-11-13 | GADICKE ANSBERT 10% owner | Sale 10b5-1 | −90,951 | $0.98 | $89K | 5,600,240 |
| 2025-11-13 | EVNIN LUKE Director | Sale 10b5-1 | −58,372 | $0.98 | $57K | 3,592,061 |
| 2025-11-12 | MPM BioVentures 2014, L.P. 10% owner | Sale 10b5-1 | −40,669 | $1.09 | $44K | 5,691,191 |
| 2025-11-12 | GADICKE ANSBERT 10% owner | Sale 10b5-1 | −40,669 | $1.09 | $44K | 5,691,191 |
| 2025-11-12 | EVNIN LUKE Director | Sale 10b5-1 | −26,101 | $1.09 | $28K | 3,650,433 |
| 2025-11-11 | MPM BioVentures 2014, L.P. 10% owner | Sale 10b5-1 | −55,810 | $1.14 | $64K | 5,731,860 |
| 2025-11-11 | GADICKE ANSBERT 10% owner | Sale 10b5-1 | −55,810 | $1.14 | $64K | 5,731,860 |
| 2025-11-11 | EVNIN LUKE Director | Sale 10b5-1 | −35,818 | $1.14 | $41K | 3,676,534 |
| 2025-11-10 | MPM BioVentures 2014, L.P. 10% owner | Sale 10b5-1 | −48,570 | $1.18 | $57K | 5,787,670 |
| 2025-11-10 | GADICKE ANSBERT 10% owner | Sale 10b5-1 | −48,570 | $1.18 | $57K | 5,787,670 |
| 2025-11-10 | EVNIN LUKE Director | Sale 10b5-1 | −31,172 | $1.18 | $37K | 3,712,352 |
| 2025-11-07 | MPM BioVentures 2014, L.P. 10% owner | Sale 10b5-1 | −68,480 | $1.11 | $76K | 5,836,240 |
| 2025-11-07 | GADICKE ANSBERT 10% owner | Sale 10b5-1 | −68,480 | $1.11 | $76K | 5,836,240 |
| 2025-11-07 | EVNIN LUKE Director | Sale 10b5-1 | −43,950 | $1.11 | $49K | 3,743,524 |
| 2025-11-06 | MPM BioVentures 2014, L.P. 10% owner | Sale 10b5-1 | −54,452 | $1.21 | $66K | 5,904,720 |
| 2025-11-06 | GADICKE ANSBERT 10% owner | Sale 10b5-1 | −54,452 | $1.21 | $66K | 5,904,720 |
| 2025-11-06 | EVNIN LUKE Director | Sale 10b5-1 | −34,947 | $1.21 | $42K | 3,787,474 |
| 2025-11-05 | MPM BioVentures 2014, L.P. 10% owner | Sale 10b5-1 | −47,950 | $1.22 | $58K | 5,959,172 |
Page 7 of 17 · 335 trades